| scholarly article | Q13442814 |
| P2093 | author name string | Adel K El-Naggar | |
| Hui Sun | |||
| Avaniyapuram Kannan Murugan | |||
| Mingzhao Xing | |||
| Xiaoli Liu | |||
| Dingxie Liu | |||
| Yuan Shan | |||
| Justin Bishop | |||
| Sara Pai | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Selective response of ternary complex factor Sap1a to different mitogen-activated protein kinase subgroups | Q24605354 | ||
| Progress in molecular-based management of differentiated thyroid cancer | Q26999887 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer | Q28253304 | ||
| Highly recurrent TERT promoter mutations in human melanoma | Q29614798 | ||
| TERT promoter mutations in familial and sporadic melanoma | Q29614920 | ||
| SAP1a is a nuclear target of signaling cascades involving ERKs | Q34307408 | ||
| Molecular pathogenesis and mechanisms of thyroid cancer | Q34329018 | ||
| BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer | Q34560988 | ||
| BRAF mutation in thyroid cancer | Q36157661 | ||
| TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal | Q36762656 | ||
| Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications | Q36909410 | ||
| Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer | Q37216703 | ||
| Papillary carcinoma tall cell variant (TCV): a review | Q37696366 | ||
| Telomeres and thyroid cancer | Q37761836 | ||
| Telomerase RNA biosynthesis and processing | Q38060194 | ||
| Telomerase and the search for the end of cancer | Q38068624 | ||
| Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype | Q40084367 | ||
| Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma | Q43128951 | ||
| The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer. | Q53660179 | ||
| American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer | Q57793991 | ||
| Integration of MAP kinase signal transduction pathways at the serum response element | Q58415341 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 603-10 | |
| P577 | publication date | 2013-08-01 | |
| P1433 | published in | Endocrine-Related Cancer | Q3054004 |
| P1476 | title | Highly prevalent TERT promoter mutations in aggressive thyroid cancers | |
| P478 | volume | 20 |
| Q30367068 | 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer |
| Q39002421 | A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel ThyroSeq v.2. |
| Q33656624 | A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma |
| Q36340626 | A new POT1 germline mutation-expanding the spectrum of POT1-associated cancers. |
| Q26797390 | A new appraisal of iodine refractory thyroid cancer |
| Q47254002 | A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma. |
| Q39163637 | A six-genotype genetic prognostic model for papillary thyroid cancer |
| Q54367378 | Absence of TERT promoter mutations in primary melanocytic tumours of the central nervous system. |
| Q60954823 | Active Surveillance for Papillary Thyroid Microcarcinoma: Challenges and Prospects |
| Q90392003 | Active surveillance of low-risk papillary thyroid carcinoma: a promising strategy requiring additional evidence |
| Q38199071 | Aggressive variants of follicular cell-derived thyroid carcinomas: a cytopathologist's perspective |
| Q38838144 | Altered TERT promoter and other genomic regulatory elements: occurrence and impact |
| Q98290370 | Appraisal of radioiodine refractory thyroid cancer: advances and challenges |
| Q91643178 | Association between functional TERT promoter polymorphism rs2853669 and cervical cancer risk in South Indian women |
| Q36339926 | Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC. |
| Q35441872 | Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer |
| Q36221232 | Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis |
| Q49808093 | BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment |
| Q35985808 | BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients. |
| Q27853042 | BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence |
| Q92904521 | BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry |
| Q37109755 | BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients |
| Q36301491 | BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from Chernobyl |
| Q38954099 | Biologic and Clinical Perspectives on Thyroid Cancer |
| Q27612411 | CIViC database |
| Q26744172 | CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases |
| Q26738705 | Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications |
| Q91143231 | Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines |
| Q35554680 | Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models |
| Q55026989 | Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas. |
| Q90334968 | Clinical Routine TERT Promoter Mutational Screening of Follicular Thyroid Tumors of Uncertain Malignant Potential (FT-UMPs): A Useful Predictor of Metastatic Disease |
| Q35906046 | Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer |
| Q36560914 | Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation |
| Q38687220 | Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis |
| Q55436824 | Co-existence of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. |
| Q57210092 | Coexistence of Promoter Mutations and the V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients |
| Q40857012 | Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness |
| Q33587905 | Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group |
| Q38614394 | Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses? |
| Q27024484 | Current status and future perspectives in differentiated thyroid cancer |
| Q36014228 | Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review. |
| Q35055107 | Development and characterization of six new human papillary thyroid carcinoma cell lines. |
| Q27853057 | Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. |
| Q89099975 | Diagnostic value and lymph node metastasis prediction of a custom‑made panel (thyroline) in thyroid cancer |
| Q48915503 | Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system |
| Q57283022 | EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC |
| Q26778154 | ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome |
| Q38997020 | Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations |
| Q34624854 | Enhancer alterations in cancer: a source for a cell identity crisis |
| Q38682900 | External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society |
| Q47864324 | FNA diagnosis of poorly differentiated thyroid carcinoma. A review of the recent literature |
| Q48651339 | Follicular cell-derived thyroid cancer. |
| Q47094119 | Frequency and Significance of Ras, Tert Promoter, and Braf Mutations in Cytologically Indeterminate Thyroid Nodules: A Monocentric Case Series at a Tertiary-Level Endocrinology Unit |
| Q52911465 | Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan. |
| Q28394370 | Functional evaluation of TERT-CLPTM1L genetic variants associated with susceptibility of papillary thyroid carcinoma |
| Q35857790 | GLI1 Transcription Factor Affects Tumor Aggressiveness in Patients With Papillary Thyroid Cancers. |
| Q91756676 | GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer |
| Q90705738 | Generation and identification of a thyroid cancer cell line with stable expression of CCDC67 and luciferase reporter genes |
| Q55399312 | Genetic Polymorphism Predisposing to Differentiated Thyroid Cancer: A Review of Major Findings of the Genome-Wide Association Studies. |
| Q90291133 | Genetic alterations in anaplastic thyroid carcinoma and targeted therapies |
| Q52609129 | Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. |
| Q37225274 | Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma |
| Q48291446 | Genetic landscape of papillary thyroid carcinoma in the Chinese population. |
| Q38716479 | Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence |
| Q64065002 | Genomic Characterization of Differentiated Thyroid Carcinoma |
| Q38884271 | Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma |
| Q36618604 | Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. |
| Q92830555 | Genomics-Enabled Precision Medicine for Cancer |
| Q90376703 | Growth-associated protein 43 promotes thyroid cancer cell lines progression via epithelial-mesenchymal transition |
| Q42190157 | Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. |
| Q33591794 | Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma |
| Q38990269 | Human telomerase reverse transcriptase regulation by DNA methylation, transcription factor binding and alternative splicing (Review). |
| Q64060079 | Identification of Targetable Lesions in Anaplastic Thyroid Cancer by Genome Profiling |
| Q38787337 | Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas |
| Q52620813 | Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis. |
| Q51415479 | In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation. |
| Q91055054 | Incremental utility of expanded mutation panel when used in combination with microRNA classification in indeterminate thyroid nodules |
| Q39267161 | Indications and extent of central neck dissection for papillary thyroid cancer: An American Head and Neck Society Consensus Statement |
| Q30457044 | Inhibition of telomerase recruitment and cancer cell death |
| Q53352497 | Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions. |
| Q91728524 | Interplay between TERT promoter mutations and methylation culminates in chromatin accessibility and TERT expression |
| Q90331552 | Lack of Mutations in POT1 Gene in Selected Families with Familial Non-Medullary Thyroid Cancer |
| Q64066644 | LncRNA FOXD2-AS1 Functions as a Competing Endogenous RNA to Regulate TERT Expression by Sponging miR-7-5p in Thyroid Cancer |
| Q36716977 | Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma |
| Q58561861 | Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population |
| Q43540329 | Low frequency of TERT promoter mutations in a large cohort of gallbladder and gastric cancers |
| Q47702648 | Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms |
| Q52727349 | Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. |
| Q59133810 | Metabolomic Alterations in Thyrospheres and Adherent Parental Cells in Papillary Thyroid Carcinoma Cell Lines: A Pilot Study |
| Q88916894 | Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts |
| Q34119098 | MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology |
| Q91761497 | Microfluidic Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT Mutations in Papillary Thyroid Carcinomas |
| Q38721735 | Molecular Aberrance in Papillary Thyroid Microcarcinoma Bearing High Aggressiveness: Identifying a "Tibetan Mastiff Dog" From Puppies |
| Q94948450 | Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers |
| Q64889316 | Molecular Study of Thyroid Cancer in World Trade Center Responders. |
| Q48088782 | Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation |
| Q54164373 | Molecular analysis of residual ThinPrep material from thyroid FNAs increases diagnostic sensitivity. |
| Q34160828 | Molecular approaches to thyroid cancer diagnosis |
| Q92009380 | Molecular changes in solitary fibrous tumor progression |
| Q38243095 | Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy |
| Q52601605 | Molecular markers in well-differentiated thyroid cancer. |
| Q47295202 | Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance. |
| Q98243177 | Multiplatform molecular test performance in indeterminate thyroid nodules |
| Q26782322 | Mutation Profile of Well-Differentiated Thyroid Cancer in Asians |
| Q41143039 | Mutation of the TERT promoter leads to poor prognosis of patients with non-small cell lung cancer |
| Q37446546 | Next-generation sequence detects ARAP3 as a novel oncogene in papillary thyroid carcinoma |
| Q58550783 | Not the same thing: metastatic PTCs have a different background than ATCs |
| Q41381572 | Oncogenesis of Thyroid Cancer |
| Q92890232 | Original tumour suppressor gene polycystic kidney and hepatic disease 1-like 1 is associated with thyroid cancer cell progression |
| Q41180944 | Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters |
| Q50146629 | Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer. |
| Q27027491 | Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations |
| Q90398425 | Personalized treatment options for thyroid cancer: current perspectives |
| Q64237017 | Precise Detection of Gene Mutations in Fine-Needle Aspiration Specimens of the Papillary Thyroid Microcarcinoma Using Next-Generation Sequencing |
| Q61455782 | Prediction of novel target genes and pathways involved in tall cell variant papillary thyroid carcinoma |
| Q38416278 | Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. |
| Q39407370 | Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis |
| Q93046820 | Prognostic significance of hTERT (human telomerase reverse transcriptase) promoter region mutations C228T and C250T for overall survival in spinal chordomas |
| Q64084348 | Promoter Hypomethylation as Recurrence Predictive Marker in Well-Differentiated Thyroid Carcinomas |
| Q26769014 | Reactivation of telomerase in cancer |
| Q47719683 | Reconstruction of enhancer-target networks in 935 samples of human primary cells, tissues and cell lines |
| Q49335901 | Refractory thyroid carcinoma: which systemic treatment to use? |
| Q49358253 | Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. |
| Q38164307 | Regulatory variation: an emerging vantage point for cancer biology |
| Q47646209 | Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis. |
| Q26744271 | Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies |
| Q55053748 | Sorafenib in the treatment of thyroid cancer. |
| Q92596277 | Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer |
| Q39312867 | Surgical considerations for papillary thyroid microcarcinomas. |
| Q54310538 | Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. |
| Q89551068 | TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients |
| Q37097535 | TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer. |
| Q38744769 | TERT Promoter Mutations in Thyroid Cancer |
| Q37408393 | TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis |
| Q40858851 | TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas. |
| Q33414576 | TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities |
| Q54347306 | TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. |
| Q54220234 | TERT promoter mutation is uncommon in acral lentiginous melanoma. |
| Q88962020 | TERT promoter mutational screening as a tool to predict malignant behaviour in follicular thyroid tumours-three examples from the clinical routine |
| Q40354589 | TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors |
| Q36962382 | TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas |
| Q33682388 | TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer |
| Q50053390 | TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases |
| Q34313648 | TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas |
| Q38383121 | TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas. |
| Q37316068 | TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma |
| Q37093384 | TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes |
| Q33688439 | TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas |
| Q26770808 | TERT promoter mutations in thyroid cancer |
| Q92059913 | TERT promoter mutations in thyroid cancer: growing evidence for a predictor of poor outcome |
| Q43740263 | TERT promoter mutations predict worse survival in laryngeal cancer patients |
| Q89287810 | TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma |
| Q90626754 | Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis |
| Q41233717 | Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma |
| Q39328851 | Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. |
| Q36618268 | Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors |
| Q52726708 | Telomerase Reverse Transcriptase Polymorphism rs2736100: A Balancing Act between Cancer and Non-Cancer Disease, a Meta-Analysis. |
| Q38232447 | Telomerase promoter mutations in cancer: an emerging molecular biomarker? |
| Q92927346 | Telomerase reverse transcriptase alterations in human cancers: Diagnosis, prognosis, and therapeutic implications |
| Q47266315 | Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer. |
| Q91028354 | Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population |
| Q34396480 | Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma |
| Q26739948 | Telomerase: The Devil Inside |
| Q55443450 | Telomere Maintenance Mechanisms in Cancer. |
| Q98158989 | Telomeres and telomerase in oncogenesis |
| Q87671724 | The Role and Importance of Molecular Tests in Approach to Thyroid Nodules |
| Q90596932 | The Solo Play of TERT Promoter Mutations |
| Q33709979 | The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors |
| Q39076273 | The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas |
| Q58453418 | The management of thyroid nodules and cancer in the molecular era |
| Q38903424 | The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. |
| Q90339275 | The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer |
| Q26781886 | The search for cis-regulatory driver mutations in cancer genomes |
| Q38844362 | Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives. |
| Q42318053 | Thyroglobulin in Metastatic Thyroid Cancer: Culprit or Red Herring? |
| Q40971151 | Thyroid cancers: from epidemiology to molecular biology |
| Q50865317 | Thyroid gland: Mutations identified in thyroid cancer. |
| Q26739925 | Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene |
| Q90917856 | Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation |
| Q37605033 | Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. |
| Q47185839 | Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations |
| Q38760235 | Understanding TERT Promoter Mutations: A Common Path to Immortality. |
| Q34152070 | Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer |
| Q33570056 | Update: the status of clinical trials with kinase inhibitors in thyroid cancer |
| Q92539491 | Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study |
| Q38389256 | When thyroid carcinoma goes bad: a morphological and molecular analysis |
| Q52878849 | ZCCHC12, a novel oncogene in papillary thyroid cancer. |
Search more.